EyePoint, Inc. (NASDAQ: EYPT) announced it has completed enrollment in two global Phase 3 clinical trials — COMO and CAPRI ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE